Specialty Pharmacy Software Features: Core Modules and Daily Workflows for a US Specialty Pharmacy and Manufacturer Hub Provider

Three Structural Decisions Before Any Module

Three decisions in this build are structural rather than functional, and they precede any list of specialty pharmacy software features because each is a boundary rather than a capability.

Assistance routing bifurcates on payer type as a hard block, so the data model must establish payer type early and reliably and the enrollment path must be physically unavailable to federally insured patients. Manufacturer reporting is a bounded output defined per program, not an export pointed at a data set. And dispensing conditions stop the process rather than warning about it.

All three are architecture. None is a setting, and implementing any of them as a rule somebody configures builds the wrong thing.

After those, the modules follow the patient journey. These features are the product layer of the full custom software development guide to custom specialty pharmacy hub platform development, delivered through web application development for the staff who run it.

Referral Intake and Benefits Investigation, Build First

Referrals Arrive Messily

Prescriber offices send enrollment forms by fax, through portals, by electronic prescription and occasionally by telephone, frequently incomplete. Intake accepts every channel, extracts what it can for human verification, and identifies what is missing so one call resolves it rather than three.

Payer Type Established Accurately

The most consequential field in the system, since it determines which assistance path is available. Established at intake, verified against eligibility responses rather than a form, and monitored for change, since a patient aging into Medicare mid-therapy changes what they may receive.

Investigation With Its Provenance

Coverage, benefit type, cost share, utilization management requirements and network restrictions recorded with source, date and reference number, since plans change positions and a documented response supports an appeal. Re-verification at plan year boundaries and on circumstance change.

Case Aging by Stage

Not overall time, which tells an operations lead nothing actionable, but time at authorization, assistance and scheduling, each with its own expectation, since most delay is queue time rather than work time.

Extracting structured data from referral forms and benefit responses for human verification is reasonable AI integration and adoption work, with the boundary in the same sentence: it never determines eligibility, decides an authorization, scores a patient for discontinuation risk or makes a clinical determination. The mechanics behind this layer are covered in Automated Benefits Investigation, Copay and Foundation Assistance Enrollment, Manufacturer Limited Distribution Data Reporting and Injection Training Scheduling.

Prior Authorization and Assistance

Authorization submission with payer requirements referenced, so the specialist knows what the plan wants before submitting rather than after a denial. Clinical documentation assembled from what the prescriber supplied with gaps identified specifically, and status tracked and chased, since authorizations stall silently.

Appeal workflows with timelines, since a meaningful proportion of specialty authorizations succeed on appeal and a case abandoned at first denial is a patient without therapy. Assistance screening running in parallel rather than after authorization, since the two are independent.

Routing bifurcated structurally on payer type: copay enrollment available only where payer type permits, and physically unavailable otherwise rather than warned against.

The foundation referral path built properly for federally insured patients, with disease state funding status tracked, since a patient referred to a closed fund needs another option today. Manufacturer separation preserved absolutely in that path, and free goods, bridge and quick-start programs where offered.

And financial counseling documented, since accreditation addresses it and patients deserve a clear picture of what they will pay. Most of these features exist in the shape they do because a regulation or an agreement requires it, as set out in URAC and ACHC Specialty Accreditation, HIPAA, Manufacturer Data Reporting Agreements, Anti-Kickback Limits on Patient Assistance and REMS Program Requirements.

Dispensing, REMS and Clinical Services

Limited distribution eligibility checked, since a pharmacy outside a network cannot dispense and the patient needs rerouting rather than delay.

REMS conditions verified as a block on dispensing, with verification recorded as performed by the required person through the required mechanism, and monitoring intervals tracked where a program requires laboratory results before further dispensing.

Pharmacist clinical review with interaction and appropriateness checking, and counseling documented to the standard accreditation expects.

Shipment coordination with the patient, since specialty shipments frequently require signature and cold chain handling and a failed delivery of a refrigerated biologic is a wasted high-value product and a delayed dose, with cold chain documentation where applicable.

Injection and infusion training scheduling, including field nurse visits where provided, coordinated against the shipment so the patient has the drug when the nurse arrives. Patient education delivered in a form the patient can use, in the languages the population speaks.

And supplies and ancillaries, routinely forgotten, leaving a patient holding a syringe with no sharps container.

Adherence, Outcomes and Reporting

Outreach scheduled against clinical protocols tied to the therapy and its tolerability profile, not against a model of who might stop. That scheduling and workload routing across the coordination team are legitimate AI product and agent development work, with the boundary in the same sentence: it never scores patients for discontinuation risk, determines eligibility, decides an authorization or makes a clinical determination.

Calls documented as clinical encounters with symptoms, technique concerns and questions recorded, with side effect escalation to a pharmacist or prescriber and adverse event reporting where obligations apply.

Refill coordination as logistics, with contact ahead of the run-out date, and therapy changes, holds and discontinuations recorded as clinical outcomes with their reason rather than as losses.

Accreditation performance measurement, which requires defined metrics collected consistently and is standing rather than annual. These are the specialty pharmacy software features auditors examine.

Manufacturer reporting as a bounded output per program with field-level control, de-identification by construction, and an audit record of what was sent under which agreement version, with payer reporting where contracts require it.

Operational reporting on time to therapy by stage, case volumes and workload. And the exclusion stated in the module: persistence is never a conversion metric and no outreach comes from discontinuation-risk scoring.

Portals and the People Using Them

The coordinator workspace, where most of the hours in this business are spent, deserves the design attention usually given to patient-facing screens.

Work queues organized by what is actionable rather than by case, since coordinators work items not patients.

A prescriber portal for referral submission, status and documents, since the office frequently holds what everybody is waiting for.

A patient portal for status, refill requests, shipment tracking and education, used narrowly since many in this population prefer a telephone call. That is the honest scope for custom mobile app development here, and Android app development matters within it for equitable access.

Refill scheduling, shipment status and appointment confirmation suit AI chatbot development, while clinical questions, side effects, dosing, assistance eligibility, coverage outcomes and a patient considering stopping go to a qualified person.

Accessibility taken seriously, since patients on specialty therapies include people with visual, motor and cognitive impairments arising from their conditions, and language access, which affects whether a patient understands their therapy.

Field nurse documentation for in-home visits, telephony integration with recording where the organization records, secure messaging across all parties, and a clear escalation route to a person from any patient-facing surface.

Where Organizations Diverge

A dispensing specialty pharmacy owns the full journey through dispensing and clinical services.

A hub service provider contracted by a manufacturer performs access and support services without dispensing.

A health system specialty pharmacy integrates with the health record and treats patients already in its care, changing both data flow and clinical context.

A limited distribution participant works within network conditions constraining which patients it serves, and an organization covering several therapeutic areas carries different protocols, REMS programs and agreements per drug.

One with field nursing carries scheduling, licensure and supervision of a distributed workforce, and one serving a largely federally insured population lives in the foundation path rather than the copay path.

And one seeking accreditation for the first time carries documentation and measurement requirements it may not have.

The payer bifurcation applies identically to all of them.

Conclusion

Settle the three structural decisions before any module, since each is a boundary built into the architecture rather than a rule somebody configures.

Establish payer type accurately and monitor it, since it determines what help a patient may receive, and build the foundation path as a first-class workflow.

And measure case aging by stage, since the queue rather than the work is where delay lives. That is the order to take through these specialty pharmacy software features with the software companies in the United States quoting you.

If you are defining requirements, measuring your median time to therapy broken down by stage is the number that will show where your patients are actually waiting.

FAQ